Evaluating the administration costs of biologic drugs: development of a cost algorithm
{{output}}
Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses... ...
